Replies to post #221376 on Biotech Values

[DewDiligence]

Tecentriq is recommended in first-line SCLC because of the results announced in Jun 2018 (#msg-141773668).

I highly doubt that anti-PDL1 agents generally are superior to anti-PD1 agents in this setting.